In more recent studies - we have seen positive research using the Kazia drug paxalisib in somewhat rare CNS disease.
But investors will love reading this information, from a top 10 medical research university in the UK......released on the web, a few hours ago..... from the Centre for Biomedical Sciences, School of Biological Sciences, Royal Holloway University of London.
It is very deep research, which you will note.
Quote here from this London Royal Holloway University - which highlights just absolute stunning new information, as to the potential of paxalisib.
_______________________________________________________________________
Enhanced Sestrin expression through Tanshinone 2A treatment improves PI3K-dependent inhibition of glioma growth
- Article
- Open Access
- Published: 19 May 2023
Cell Death Discovery volume 9, Article number: 172 (2023) Cite this article
- Judith Schaf,
- Sonia Shinhmar,
- Qingyu Zeng,
- Olivier E. Pardo,
- Philip Beesley,
- Nelofer Syed &
- Robin S. B. Williams
Inactivation of mTORC1 through combinatory treatment with Paxalisib and T2A may provide a useful approach in treating other diseases arising from PI3K/PKB/mTORC1 dysregulation. These diseases include many cancer types such as blader [68], ovarian [69], breast [70, 71] and non-small cell lung cancers [72] as well as inflammatory diseases like restenosis and neointimal hyperplasia [73]. It may also provide novel approaches in the treatment of a variety of neurological diseases such as epilepsy [74,75,76], and autism spectrum disorder [77] and metabolic disorders including Type II Diabetes Mellitus [78]. Thus, using PI3K inhibitors and T2A in combination may be beneficial to the treatment of a range of diseases.
-------------------------------------------------------------------
It is fair to scrutinize, exactly who produced this highly detailed study. So more below on the Royal Holloway University, London.
From Wikipedia, the free encyclopedia
Affiliations| ACUAMBAEUAUniversities UK
Column 1 Column 2 Column 3 Column 4 Column 5 Column 6 Column 7 Column 8 Column 9 Column 10 Column 11 Column 12 Column 13 Column 14 Column 15 Column 16 Column 17 0 {caption}Royal Holloway, University of London{/caption} 1 2 Motto Esse quam videri (Latin) 3 Motto in English 4 To be, rather than to seem (to be) 5 Type Public research university 6 Established 1849: Bedford College1879: Royal Holloway College1900: became a constituent college of the University of London1985: merger of Bedford College and Royal Holloway College 7 Parent institution 8 University of London 9 Endowment £86.1 million (2022)[1] 10 Budget £201.1 million (2021–22)[1] 11 Chancellor The Princess Royal(as Chancellor of the University of London) 12 Principal Julie Sanders[2] 13 Academic staff 14 1,165 (2021/22)[3] 15 Administrative staff 16 1,055 (2021/22)[3] 17 Students 12,480 (2021/22)[4] 18 Undergraduates 9,685 (2021/22)[4] 19 Postgraduates 2,795 (2021/22)[4] 20 Location Egham, Surrey, England 21 Campus Suburban 22 Colours
Column 1 0
Website| www.royalholloway.ac.uk
[/table]
Royal Holloway, University of London (RHUL), formally incorporated as Royal Holloway and Bedford New College, is a public research university and a constituent college of the federal University of London. It has six schools, 21 academic departments and approximately 10,500 undergraduate and postgraduate students from over 100 countries.[5] The campus is located west of Egham, Surrey, 19 miles (31 km) from central London.
Royal Holloway maintains strong links and exchange programmes with institutions in the United States, Canada, Australia, and Hong Kong, notably the University of California & Yale University, the University of Toronto, the University of Melbourne and the University of Hong Kong.[7]
- Forums
- ASX - By Stock
- KZA
- High Quality Research-Non Cancer Disease
High Quality Research-Non Cancer Disease
-
- There are more pages in this discussion • 34 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add KZA (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
MTL
MANTLE MINERALS LIMITED
Nick Poll, Executive Director
Nick Poll
Executive Director
SPONSORED BY The Market Online